These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6250981)

  • 1. Cefotaxime pharmacokinetics following a single intravenous dose to patients with varying renal function.
    Nielsen OS; Toothaker RD; Bundtzen RW; Craig WA; Welling PG; Madsen PO
    Infection; 1980; 8 Suppl 3():S 305-9. PubMed ID: 6250981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
    Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.
    Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ceftazidime in normal and uremic subjects.
    Leroy A; Leguy F; Borsa F; Spencer GR; Fillastre JP; Humbert G
    Antimicrob Agents Chemother; 1984 May; 25(5):638-42. PubMed ID: 6375562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.
    Ings RM; Reeves DS; White LO; Bax RP; Bywater MJ; Holt HA
    J Pharmacokinet Biopharm; 1985 Apr; 13(2):121-42. PubMed ID: 4057054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data.
    Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses.
    Neu HC; Aswapokee P; Fu KP; Ho I; Matthijssen C
    Clin Pharmacol Ther; 1980 May; 27(5):677-85. PubMed ID: 6245831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.
    Chodos J; Francke EL; Saltzman M; Neu HC
    Ther Drug Monit; 1981; 3(1):71-4. PubMed ID: 6262952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doses of antibiotic in patients with renal insufficiency.
    Ohkawa M; Kuroda K
    Clin Ther; 1981; 4 Suppl A():124-32. PubMed ID: 6275994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.
    Ings RM; Fillastre JP; Godin M; Leroy A; Humbert G
    Rev Infect Dis; 1982; 4 Suppl():S379-91. PubMed ID: 6294787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefodizime in patients with various degrees of renal failure.
    Loffreda A; Lampa E; Lucarelli C; Amorena M; Contaldi C; Calderaro V; Rossi F
    Chemotherapy; 1999; 45(1):1-7. PubMed ID: 9876203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease.
    Wise R; Wright N; Wills PJ
    Antimicrob Agents Chemother; 1981 Apr; 19(4):526-31. PubMed ID: 6264849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Kinetics of cefotaxime in healthy subjects (author's transl)].
    Acar JF; Guibert J; Kitzis MD
    Nouv Presse Med; 1981 Feb; 10(8):559-63. PubMed ID: 6259593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefotaxime in patients after liver transplantation.
    Kuse E; Vogt P; Rosenkranz B
    Infection; 1990; 18(5):268-72. PubMed ID: 2276819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefodizime in elderly patients with moderate or severe renal impairment.
    Veyssier P; Devillers A; Domart Y; Fourtillan JB; Bryskier A; Procyk T
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():77-81. PubMed ID: 2074255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
    Conte JE
    J Clin Pharmacol; 1994 Nov; 34(11):1066-70. PubMed ID: 7876397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of cefixime in patients with impaired renal function].
    Maeda H; Sako M; Fujii A; Yamazaki H; Kawabata G; Harada M; Arakawa S; Umezu K; Kamidono S; Ishigami J
    Jpn J Antibiot; 1986 Oct; 39(10):2716-20. PubMed ID: 3806957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.